Gencurix, Inc. is engaged in developing and manufacturing of cancer diagnostic test kits. Its products include GenesWell BCT, GenesWell ddEGFR Mutation Test, GenesWell CDx EGFR Mutation Test, and GenesWell ddEGFR Mutation Test. The company was founded on September 21, 2011 and is headquartered in Seoul, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company